Three successful diagnostic exits
Changing How—and When—Cancer Is Found
Our Mission
Revolutionizing early cancer detection with noninvasive, AI-powered urine tests
Fueling our growth through world-class life science accelerators
Accelerators (Newest → Oldest)
Mayo Clinic & ASU
2025 MedTech Accelerator
Flagship program of the Mayo Clinic and Arizona State University Alliance for Health Care. Supports early-stage health tech companies with expert mentoring, personalized strategy, and clinical validation opportunities
Project Healthcare
Commercialization
Backed by the Nashville Entrepreneur Center, this accelerator helps healthcare startups scale by connecting them with customers, capital, and industry experts
LifeX
Pre-Commercialization
Supports early-stage healthcare companies preparing to bring science-driven technologies to market, with a focus on clinical and operational readiness
MassChallenge
Early Stage
Selected from over 1,300 startups in a globally competitive, equity-free accelerator for high-impact ventures
Grounded in Science. Guided by Purpose. Focused on You.
Our Values
Accuracy
We pursue the highest standards of precision to deliver results clinicians and patients can truly rely on
Patient First
We design every experience, from sample to result, around patient comfort, access, and empowerment
Scientific Rigor
We follow peer-reviewed science, clinical validation, and robust methodologies in everything we build
Proof that the world’s watching
Recognition (Newest → Oldest)
Massachusetts AI Health Innovation Grant
Awarded by CIC to advance AI-powered cancer screening through expert software collaboration
LEAP RECIPIENT
Selected for innovation in life sciences, gaining elite legal and strategic support for growth in cancer detection
FIRST PLACE
1st place at ADLM 2024, recognized by Mayo Clinic as the top diagnostics startup among ~100 global entrants
A Personal Search for Answers Became a Shared Solution
The Story
Dragan grew disillusioned with sequencing and sought a better way. After years searching for answers to his own autoimmune disease, Matthew discovered a data-driven diagnostic approach he wished had existed sooner. Together they founded TOBY to make early detection faster, simpler, and more accessible, naming it after Sherlock Holmes’s scent-tracking bloodhound.